Vanguard Capital Management
BNTC icon

Vanguard Capital Management’s Benitec Biopharma BNTC Stock Holding History

Vanguard Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8M Buy
954,533
+22,977
+2% +$273K ﹤0.01% 2692
2026
Q1 		$9.92M Buy
+931,556
New +$10.8M ﹤0.01% 2732

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management's BNTC Position: Q2 2026 in Review

Vanguard Capital Management increased its Benitec Biopharma (BNTC) stake by 2.5% in Q2 2026, buying an estimated $273K and bringing the position to 954,533 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2692.

Vanguard Capital Management first reported a position in BNTC in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Vanguard Capital Management held 954,533 shares of Benitec Biopharma worth $12.8M as of Q2 2026.
  • Vanguard Capital Management bought 22,977 Benitec Biopharma shares in Q2 2026, an estimated $273K.
  • Benitec Biopharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2692 holding.
  • Vanguard Capital Management first reported a position in Benitec Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.